Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14609985 | 0.88 | KMT2A (0.63) | SGMS2NPC1PARP1ALDH1A1LMNA | |
| SCHEMBL8674882 | 0.88 | SGMS2 (0.54) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL28181099 | 0.87 | CHRM4 (0.53) | SGMS2NPC1HTTGAAMAPT | |
| SCHEMBL6476026 | 0.87 | SGMS2 (0.52) | SGMS2NPC1HTTGAAALDH1A1 | |
| SCHEMBL5296788 | 0.87 | KMT2A (0.58) | SGMS2NPC1HTTPARP1ALDH1A1 | |
| SCHEMBL29254214 | 0.87 | PARP1 (0.54) | SGMS2NPC1HTTPARP1LMNA | |
| SCHEMBL2331143 | 0.85 | MAPT (0.65) | SGMS2NPC1HTTGAAMAPT | |
| SCHEMBL29433417 | 0.85 | SGMS2 (0.66) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL112903 | 0.85 | SGMS2 (0.66) | SGMS2NPC1HTTGAAPARP1 | |
| SCHEMBL9696207 | 0.85 | SGMS2 (0.66) | SGMS2NPC1HTTGAAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101580507-A | Novel antitumor compound and preparation method and application thereof | UNIV EAST CHINA SCIENCE & TECH (CN) | 2009-11-18 | — | — | CN | claimed |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | ALLEN DARIN ARTHUR (US) | 2003-12-18 | — | — | US | claimed |
| CN-1425021-A | Gallotannins and ellagitannins as modulators of cytokine release | PENN STATE RES FOUND (US) | 2003-06-18 | — | — | CN | claimed |
| EP-1242366-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001044172-A1 | SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | EPIVARIO, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | EPIVARIO, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| CN-114423766-B | Pentane derivatives for the treatment of bacterial infections | 丹诺医药(苏州）有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023249470-A1 | NOVEL POMALIDOMIDE DERIVATIVES AND PREPARATION METHOD THEREFOR | 주식회사 아이비스바이오 | 2023-12-28 | — | — | WO | disclosed |
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| EP-3196191-B1 | 2-ALKYLOXY BENZENE FORMYL ARYLAMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | UNIV FUDAN (CN) | 2023-04-19 | — | — | EP | disclosed |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2022-09-29 | — | — | US | disclosed |
| US-5096613-A | OPTICALLY ACTIVE FLUORINE-CONTAINING ALCOHOL COMPOUNDS AND LIQUID CRYSTAL COMPOUNDS THEREFROM | SHOWA SHELL SEKIYU KABUSHIKI KAISHA (JP) | 1992-03-17 | — | — | US | disclosed |
| US-5059611-A | Treating psoriasis and modifying calcium homeostatis | ALLERGAN, INC. (US) | 1991-10-22 | — | — | US | disclosed |
| EP-0413585-A1 | Carboxylate compounds, liquid crystal compositions containing said compounds and liquid crystal element | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-02-20 | — | — | EP | disclosed |
| EP-0369812-A2 | Anti-inflammatory 5-hydroxy-2-furanones | ALLERGAN, INC (US) | 1990-05-23 | — | — | EP | disclosed |
| EP-0008402-B1 | 2-(O-HYDROXYPHENYL)-PYRROLE AND PROCESS FOR ITS PREPARATION | BASF Aktiengesellschaft (DE) | 1982-06-02 | — | — | EP | disclosed |
| EP-0008108-B1 | AMINOPROPANOL DERIVATIVES OF 2-(O-HYDROXYPHENYL)-PYRROLES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1982-05-05 | — | — | EP | disclosed |
| US-4267187-A | AS PHARMACEUTICALS IN TREATING CARDIOVASCULAR DISSORDERS | BASF AKTIENGESELLSCHAFT (DE) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186433-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | SGMS2 73/4885NPC1 2991/4885HTT 4784/4885 |
| US-20030232789-A1 | Salicylamides as serine protease and factor xa inhibitors | TFPI, HABP2, PLAT | SGMS2 2663/4885NPC1 4290/4885HTT 4302/4885 |
| US-20220305010-A1 | ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, GLS2, ADSS2 | SGMS2 73/4885NPC1 2991/4885HTT 4784/4885 |
| US-12133852-B2 | ACSS2 inhibitors and methods of use thereof | ACSS2, GLS2, ADSS2 | SGMS2 73/4885NPC1 2991/4885HTT 4784/4885 |
| US-20020052343-A1 | Salicylamides as serine protease inhibitors | TFPI, SERPINE1, HABP2 | SGMS2 2614/4885NPC1 4012/4885HTT 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.